Pikralida

Pikralida is a dynamic biotechnology company dedicated to the research and development of innovative therapies. With a focus on advancing medical science, Pikralida integrates its own research and development (R&D) efforts with Contract Research Organization (CRO) services, creating a hybrid business model that drives both innovation and commercial success.

Located at Bukowska 70 / B424, Poznań, wielkopolskie 60-812, PL (Primary address) and Rydygiera 8 bud. 13, Warszawa, mazowieckie 01-793, PL, Pikralida is committed to building a high-value portfolio of projects. The company’s flagship development program centers around PKL-021 (marimastat), a subnanomolar matrix metalloprotease (MMP) inhibitor with broad therapeutic potential. Pikralida is actively advancing a pipeline of novel applications, targeting neuroprotection (stroke) and snakebite envenoming, among other high-impact therapeutic areas.

Pikralida also operates as a specialized CRO, offering tailored research and development services to biotech and pharmaceutical companies. With global ambitions and a commitment to excellence, Pikralida is poised to make significant contributions to the biotechnology landscape. We invite the manager of Pikralida to create a customized and exclusive company showcase and product listing on our platform to further enhance their commercial development.